Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dabigatran

Sanofi reception

Sanofi and Boehringer in $20bn asset swap negotiations

Want to exchange their consumer health and veterinary interests

- PMLiVE

NICE backs Xtandi but turns down Zytiga

Astellas and Medivation's pre-chemotherapy prostate cancer drug receives support

- PMLiVE

NICE changes stance on AZ’s Lynparza after concessions

NHS patients in England and Wales to get ovarian cancer drug

- PMLiVE

Boehringer’s coughing beat box drives its message home

Throat hacking performance raises awareness of lung cancer symptom

- PMLiVE

Alexion’s rare bone disorder therapy rejected by NICE

Draft guidance rules Strensiq does not have a compelling enough evidence base

National Institute for Health and Care Excellence NICE logo

NICE recommends two drugs for ovarian cancer but rejects three

Paclitaxel and Caelyx given preliminary nod

National Institute for Health and Care Excellence NICE logo

BioMarin’s real world data sways NICE on orphan drug Vimizim

Rare genetic disorder treatment recommended in final draft guidance

- PMLiVE

Cancer Drugs Fund overhaul promises faster access to drugs

Proposals suggest turning CDF into 'managed access' fund

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

Boehringer Ingelheim headquarters

Boehringer pledges €11bn to fund R&D drive

Plans more external collaborations as it appears to reduce spending

- PMLiVE

Boehringer appoints new chairman of the board

Hubertus vonBaumbach will succeed Andreas Barner

- PMLiVE

Boehringer takes third-generation NSCLC drug into pivotal trials

Startsphase II study of BI 1482694 in patients who test positive for T790M mutation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links